Dryocrassin ABBACAS# 12777-70-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 12777-70-7 | SDF | Download SDF |
| PubChem ID | 3082025 | Appearance | Yellow powder |
| Formula | C43H48O16 | M.Wt | 820.81 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2-acetyl-4-[[3-[[3-[(5-acetyl-2,6-dihydroxy-3,3-dimethyl-4-oxocyclohexa-1,5-dien-1-yl)methyl]-5-butanoyl-2,4,6-trihydroxyphenyl]methyl]-5-butanoyl-2,4,6-trihydroxyphenyl]methyl]-3,5-dihydroxy-6,6-dimethylcyclohexa-2,4-dien-1-one | ||
| SMILES | CCCC(=O)C1=C(C(=C(C(=C1O)CC2=C(C(C(=O)C(=C2O)C(=O)C)(C)C)O)O)CC3=C(C(=C(C(=C3O)C(=O)CCC)O)CC4=C(C(C(=O)C(=C4O)C(=O)C)(C)C)O)O)O | ||
| Standard InChIKey | PRVKSKWNDSLRBY-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C43H48O16/c1-9-11-24(46)28-32(50)18(30(48)20(34(28)52)14-22-36(54)26(16(3)44)40(58)42(5,6)38(22)56)13-19-31(49)21(35(53)29(33(19)51)25(47)12-10-2)15-23-37(55)27(17(4)45)41(59)43(7,8)39(23)57/h48-57H,9-15H2,1-8H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Orally administered dryocrassin ABBA provides mice protection against avian influenza virus H5N1 by inhibiting inflammation and reducing virus loads; dryocrassin ABBA is a potential novel lead compound which has antiviral effects on amantadine-resistant avian influenza virus H5N1 infection. 2. Dryocrassin ABBA can significantly suppress tumor growth, without major side effects; suggests that it may induce apoptosis in human hepatocellular carcinoma cells through a caspase-mediated mitochondrial pathway. |
| Targets | Influenza virus | p53 | Bcl-2/Bax | Caspase | IL Receptor | TNF-α |
Dryocrassin ABBA Dilution Calculator
Dryocrassin ABBA Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.2183 mL | 6.0915 mL | 12.1831 mL | 24.3662 mL | 30.4577 mL |
| 5 mM | 0.2437 mL | 1.2183 mL | 2.4366 mL | 4.8732 mL | 6.0915 mL |
| 10 mM | 0.1218 mL | 0.6092 mL | 1.2183 mL | 2.4366 mL | 3.0458 mL |
| 50 mM | 0.0244 mL | 0.1218 mL | 0.2437 mL | 0.4873 mL | 0.6092 mL |
| 100 mM | 0.0122 mL | 0.0609 mL | 0.1218 mL | 0.2437 mL | 0.3046 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2'-O-Methylbroussonin A
Catalog No.:BCN7318
CAS No.:127757-13-5
- SKF 97541
Catalog No.:BCC6626
CAS No.:127729-35-5
- Radicicol
Catalog No.:BCC2131
CAS No.:12772-57-5
- (2R)-5,7-Dimethoxyflavanone
Catalog No.:BCN7806
CAS No.:1277188-85-8
- 9alpha,11-Dihydroxydrim-7-en-6-one
Catalog No.:BCN7225
CAS No.:127681-58-7
- PF-4989216
Catalog No.:BCC6468
CAS No.:1276553-09-3
- Cadherin Peptide, avian
Catalog No.:BCC1018
CAS No.:127650-08-2
- Oleficin
Catalog No.:BCN1848
CAS No.:12764-54-4
- Fananserin
Catalog No.:BCC7440
CAS No.:127625-29-0
- PF-3644022
Catalog No.:BCC6136
CAS No.:1276121-88-0
- HS-173
Catalog No.:BCC5363
CAS No.:1276110-06-5
- CNX1351
Catalog No.:BCC6375
CAS No.:1276105-89-5
- Saquinavir
Catalog No.:BCC1921
CAS No.:127779-20-8
- C-type natriuretic peptide (1-22) (human, rat, swine)
Catalog No.:BCC6033
CAS No.:127869-51-6
- CGP 37849
Catalog No.:BCC7078
CAS No.:127910-31-0
- CGP 39551
Catalog No.:BCC7053
CAS No.:127910-32-1
- 24(31)-Dehydrocarboxyacetylquercinic acid
Catalog No.:BCN1589
CAS No.:127970-62-1
- CU CPT 4a
Catalog No.:BCC6319
CAS No.:1279713-77-7
- Teucrin A
Catalog No.:BCC8259
CAS No.:12798-51-5
- Ursodiol
Catalog No.:BCC4945
CAS No.:128-13-2
- Pregnanolone
Catalog No.:BCC7736
CAS No.:128-20-1
- Sennoside B
Catalog No.:BCN1003
CAS No.:128-57-4
- Arvanil
Catalog No.:BCC7026
CAS No.:128007-31-8
- erythro-1-(4-Hydroxy-3-methoxyphenyl)propane-1,2-diol
Catalog No.:BCN1588
CAS No.:1280602-81-4
Dryocrassin ABBA Induces Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells Through a Caspase-Dependent Mitochondrial Pathway.[Pubmed:27221859]
Asian Pac J Cancer Prev. 2016;17(4):1823-8.
BACKGROUND: Biological and pharmacological activities of Dryocrassin ABBA, a phloroglucinol derivative extracted from Dryopteris crassirhizoma, have attracted attention. In this study, the apoptotic effect of Dryocrassin ABBA on human hepatocellular carcinoma HepG2 cells was investigated. MATERIALS AND METHODS: We tested the effects of Dryocrassin ABBA on HepG2 in vitro by MTT, flow cytometry, real-time PCR, and Western blotting. KM male mice were used to detect the effect of Dryocrassin ABBA on H22 cells in vivo. RESULTS: Dryocrassin ABBA inhibited the growth of HepG2 cells in a concentration-dependent manner. After treatment with 25, 50, and 75 mug/mL Dryocrassin ABBA, the cell viability was 68%, 60% and 49%, respectively. Dryocrassin ABBA was able to induce apoptosis, measured by propidium iodide (PI)/annexin V-FITC double staining. The results of real-time PCR and Western ting showed that Dryocrassin ABBA up-regulated p53 and Bax expression and inhibited Bcl-2 expression which led to an activation of caspase-3 and caspase-7 in the cytosol, and then induction of cell apoptosis. In vivo experiments also showed that Dryocrassin ABBA treatment significantly suppressed tumor growth, without major side effects. CONCLUSIONS: Overall, these findings provide evidence that Dryocrassin ABBA may induce apoptosis in human hepatocellular carcinoma cells through a caspase-mediated mitochondrial pathway.
Application of a sensitive and accurate LC-MS/MS method for determination of dryocrassin ABBA in rat plasma for a bioavailability study.[Pubmed:24497015]
Biomed Chromatogr. 2014 Sep;28(9):1205-11.
A sensitive and accurate liquid chromatography-tandem mass spectrometry method was developed and validated for the determination of Dryocrassin ABBA, a potential active component isolated from Dryopteris crassirhizoma, in rat plasma. Chromatographic separation was achieved on a Zorbax SB-C18 column (50 x 2.1 mm, 1.8 microm), with elution consisting of eluent (A) 10 mm ammonium acetate in methanol containing 0.1% formic acid and (B) 10 mm ammonium acetate in water containing 0.1% formic acid (A:B = 99:1, v/v) at a flow rate of 0.3 mL/min. Multiple reaction monitoring mode was used to monitor the precursor-product ion transitions of m/z 819.3 --> 403.4 for Dryocrassin ABBA and m/z 426.2 --> 409.2 for internal standard. This assay exhibited a good linearity with a correlation coefficient >0.99 and showed no endogenous interference with the analyte and internal standard. The lower limit of quantification of Dryocrassin ABBA was 4 ng/mL in 50 muL of rat plasma. The method was successfully applied in the pharmacokinetic study of Dryocrassin ABBA in rats after intravenous (2.35 mg/kg) and oral (23.5 mg/kg) doses of Dryocrassin ABBA. The oral bioavailability (F) of Dryocrassin ABBA was estimated to be 50.1%. Our study is the first to clarify the pharmacokinetic behaviors of Dryocrassin ABBA in animals.
